Vickesh Myer Net Worth

The estimated Net Worth of Vickesh Myer is at least $11.3 Thousand dollars as of 18 March 2019. Vickesh Myer owns over 3,000 units of Editas Medicine Inc stock worth over $11,340 and over the last 6 years Vickesh sold EDIT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Vickesh Myer EDIT stock SEC Form 4 insiders trading

Vickesh has made over 10 trades of the Editas Medicine Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Vickesh exercised 3,000 units of EDIT stock worth $1,950 on 18 March 2019.

The largest trade Vickesh's ever made was exercising 14,000 units of Editas Medicine Inc stock on 17 July 2018 worth over $83,020. On average, Vickesh trades about 6,333 units every 23 days since 2018. As of 18 March 2019 Vickesh still owns at least 3,000 units of Editas Medicine Inc stock.

You can see the complete history of Vickesh Myer stock trades at the bottom of the page.

What's Vickesh Myer's mailing address?

Vickesh's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.

Insiders trading at Editas Medicine Inc

Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr, and Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.

What does Editas Medicine Inc do?

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Complete history of Vickesh Myer stock trades at Editas Medicine Inc

Editas Medicine Inc executives and stock owners

Editas Medicine Inc executives and other stock owners filed with the SEC include:

• Cynthia Collins,
  President, Chief Executive Officer, Director
• Charles Albright,
  Executive Vice President, Chief Scientific Officer
• Dr. Bruce E. Eaton Ph.D.,
  Exec. VP & Chief Bus. Officer
• Michelle Robertson,
  CFO, Principal Accounting Officer, Treasurer & Assistant Sec.
• David Scadden,
  Independent Director
• James Mullen,
  Independent Chairman of the Board
• Jessica Hopfield,
  Independent Director
• Andrew Hirsch,
  Independent Director
• Dr. Lisa A. Michaels M.D.,
  Exec. VP & Chief Medical Officer
• Akshay Vaishnaw,
  Independent Director
• James C. Mullen,
  Chairman, Pres & CEO
• Lisa Michaels,
  Executive Vice President, Chief Medical Officer
• Mark Mullikin,
  Investor Relations Officer
• Gad Berdugo,
  Chief Business Officer
• Harry Gill,
  Senior Vice President - Operations
• Michelle Robertson,
  Chief Financial Officer
• Dr. Gilmore O'Neill,
  Pres & CEO
• Charlene Stern J.D., Ph.D.,
  Exec. VP & Gen. Counsel
• Ron Moldaver,
  Investor Relations
• Dr. J. Keith Joung M.D., Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Dr. George McDonald Church Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Charlene Stern,
  Sr. VP & Chief Legal Officer
• Dr. Mark S. Shearman,
  Exec. VP & Chief Scientific Officer
• Harry R. Gill III,
  Sr. VP of Operations
• Dr. David R. Liu,
  Co-Founder & Scientific Advisory Board Member
• Dr. J. Keith Joung,
  Co-Founder & Scientific Advisory Board Member
• Dr. George M. Church,
  Co-Founder & Scientific Advisory Board Member
• Dr. Feng Zhang,
  Co-Founder & Scientific Advisory Board Member
• Douglas G. Cole,
  Director
• Katrine Bosley,
  President and CEO
• Kevin P Starr,
  10% owner
• Alexis Borisy,
  Director
• Alexandra Glucksmann,
  Chief Operating Officer
• Venture Management Co. Vi, ...,
  
• Ventures Fund Iv, L.P.Flags...,
  
• Kevin Bitterman,
  Director
• Gerald Frank Cox,
  Chief Medical Officer
• Ventures Fund Iv, L.P.Flags...,
  
• John Mendlein,
  Director
• Boris Nikolic,
  Director
• Andrew A. F. Hack,
  Chief Financial Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Llc Bng0,,
  10% owner
• Bernadette Connaughton,
  Director
• Elliott M. Levy,
  Director
• Vickesh Myer,
  Chief Technology Officer
• Global Investors Lp Viking ...,
  
• Global Performance Llc Viki...,
  
• James E Deerfield Mgmt Iii,...,
  
• Baisong Mei,
  EVP, CHIEF MEDICAL OFFICER
• Mark S Shearman,
  EVP, CHIEF SCIENTIFIC OFFICER
• Meeta Chatterjee,
  Director
• Bruce Eaton,
  EVP, CBO AND CTO
• Emma Reeve,
  Director
• Erick Lucera,
  EVP, CHIEF FINANCIAL OFFICER
• Gilmore Neil O'neill,
  CEO
• Linda Burkly,
  EVP, CHIEF SCIENTIFIC OFFICER